WuXi Biologics WuXi AppTec is expected to provide world-class integrated biopharmace
WuXi Biologics is a subsidiary of the WuXi AppTec Group with branches in Wuxi, Shanghai and Suzhou. As a platform for innovative companies to realize their dream of developing new drugs, WuXi AppTec is expected to provide world-class integrated biopharmaceutical R&D and manufacturing services to more innovative biotech companies at home and abroad in the future, accelerating the process of bringing innovative biopharmaceuticals to market in China for the benefit of patients.
ResearchHealthcare, Technology, Consumer Staples
WIA2020 | Rising Tech Stars 2020: Global & China's 100
ResearchReal Estate, Industrials, Financials
Tech for Global, Globalization Footprints of the Established and the New
Dada group's revenue rose nearly 30% in the third quarter, and JD's "hour purchase" cont
Looking forward to the fourth quarter of 2021, dada Group expects its total revenue to be between 2 billion yuan and 2.1 billion yuan. On the premise that the last kilometer of dada express delivery service is consistent with the comparable basis, the total revenue in the fourth quarter of 2021 will achieve a year-on-year increase of 88% to 97%.
Nov 24, 2021 11:42 AM